CEPHALON NAMES VICE PRESIDENT OF DRUG DEVELOPMENT
CEPHALON NAMES VICE PRESIDENT OF DRUG DEVELOPMENT WEST CHESTER, Pa., Dec. 16 /PRNewswire/ -- Cephalon, Inc.
(NASDAQ: CEPH) announced today the promotion of Dr. Peter Grebow to vice president, drug development, from the position of director of drug development. The announcement was made today by Dr. Frank Baldino, president and CEO of Cephalon, Inc.
"Dr. Grebow has demonstrated his team can move lead compounds from the discovery stage through preclinical testing," said Baldino. "He has been key in positioning Cephalon to file an Investigational New Drug application with FDA in the second quarter of 1992 for the use of Myotrophin (IFG-1) to treat amyotrophic lateral sclerosis." Grebow joined Cephalon in early 1991 from Rhone-Poulenc Rorer, where he was vice president of drug development for Rorer Central Research, a division of Rorer Pharmaceutical Corporation. Prior to that he was director of drug disposition for Revlon Health Care Group and then for Rorer Central Research following its acquisition of Revlon. Cephalon plans to file their first IND in the second quarter of 1992 for Myotrophin(R) (recombinant IGF-1 (Insulin-like Growth Factor)). Myotrophin is a protein made in very small amounts in humans. Research at Cephalon has shown that IGF-1 acts as a trophic factor, stimulating the growth and prolonging the life of motor neurons which are degenerating in patients with ALS. Cephalon, Inc. was founded in 1987 to discover, develop and commercialize novel therapeutic products for the treatment of stroke and neurodegenerative disorders. -0- 12/16/91 /CONTACT: Nicole Vitullo of Cephalon, 215-344-0200/ (CEPH) CO: Cephalon, Inc. ST: Pennsylvania IN: MTC SU: PER
KD-JT -- NY003 -- 2677 12/16/91 08:00 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 16, 1991|
|Previous Article:||HOLLAND AMERICA WESTOURS OFFERS 'HEARTLAND' CRUISETOUR FEATURING A LOOK AT THE ALASKA AGRICULTURAL SCENE|
|Next Article:||LASERSCOPE REJECTS ALLEGATIONS OF PATENT INFRINGEMENT|